AU2021236669A1 - Anti-ceramide antibodies - Google Patents

Anti-ceramide antibodies Download PDF

Info

Publication number
AU2021236669A1
AU2021236669A1 AU2021236669A AU2021236669A AU2021236669A1 AU 2021236669 A1 AU2021236669 A1 AU 2021236669A1 AU 2021236669 A AU2021236669 A AU 2021236669A AU 2021236669 A AU2021236669 A AU 2021236669A AU 2021236669 A1 AU2021236669 A1 AU 2021236669A1
Authority
AU
Australia
Prior art keywords
seq
amino acid
acid sequence
antigen
binding fragment
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Pending
Application number
AU2021236669A
Other languages
English (en)
Inventor
Richard Kolesnick
Raphael Levy
Arthur Tinkelenberg
Jordon Kuo-Ming WANG
Yong Wang
Yinan Wu
Current Assignee (The listed assignees may be inaccurate. Google has not performed a legal analysis and makes no representation or warranty as to the accuracy of the list.)
Ceramedix Holding LLC
Memorial Sloan Kettering Cancer Center
Original Assignee
Ceramedix Holding LLC
Memorial Sloan Kettering Cancer Center
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Ceramedix Holding LLC, Memorial Sloan Kettering Cancer Center filed Critical Ceramedix Holding LLC
Publication of AU2021236669A1 publication Critical patent/AU2021236669A1/en
Assigned to MEMORIAL SLOAN KETTERING CANCER CENTER, CERAMEDIX HOLDING, LLC reassignment MEMORIAL SLOAN KETTERING CANCER CENTER Amend patent request/document other than specification (104) Assignors: CERAMEDIX HOLDING, LLC, MEMORIAL SLOAN KETTERING CANCER CENTER, RICHARD KOLESNICK
Pending legal-status Critical Current

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/44—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material not provided for elsewhere, e.g. haptens, metals, DNA, RNA, amino acids
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A61P37/02—Immunomodulators
    • A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
    • C—CHEMISTRY; METALLURGY
    • C12—BIOCHEMISTRY; BEER; SPIRITS; WINE; VINEGAR; MICROBIOLOGY; ENZYMOLOGY; MUTATION OR GENETIC ENGINEERING
    • C12N—MICROORGANISMS OR ENZYMES; COMPOSITIONS THEREOF; PROPAGATING, PRESERVING, OR MAINTAINING MICROORGANISMS; MUTATION OR GENETIC ENGINEERING; CULTURE MEDIA
    • C12N15/00—Mutation or genetic engineering; DNA or RNA concerning genetic engineering, vectors, e.g. plasmids, or their isolation, preparation or purification; Use of hosts therefor
    • C12N15/09—Recombinant DNA-technology
    • C12N15/63—Introduction of foreign genetic material using vectors; Vectors; Use of hosts therefor; Regulation of expression
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/52—Constant or Fc region; Isotype
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/50—Immunoglobulins specific features characterized by immunoglobulin fragments
    • C07K2317/56—Immunoglobulins specific features characterized by immunoglobulin fragments variable (Fv) region, i.e. VH and/or VL
    • C07K2317/565—Complementarity determining region [CDR]
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/60—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments
    • C07K2317/62—Immunoglobulins specific features characterized by non-natural combinations of immunoglobulin fragments comprising only variable region components
    • C07K2317/622—Single chain antibody (scFv)
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/70—Immunoglobulins specific features characterized by effect upon binding to a cell or to an antigen
    • C07K2317/76—Antagonist effect on antigen, e.g. neutralization or inhibition of binding
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/90—Immunoglobulins specific features characterized by (pharmaco)kinetic aspects or by stability of the immunoglobulin
    • C07K2317/92—Affinity (KD), association rate (Ka), dissociation rate (Kd) or EC50 value

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Genetics & Genomics (AREA)
  • Immunology (AREA)
  • General Health & Medical Sciences (AREA)
  • Engineering & Computer Science (AREA)
  • Medicinal Chemistry (AREA)
  • Biochemistry (AREA)
  • Biophysics (AREA)
  • Molecular Biology (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Wood Science & Technology (AREA)
  • Biomedical Technology (AREA)
  • Biotechnology (AREA)
  • General Engineering & Computer Science (AREA)
  • Zoology (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Public Health (AREA)
  • Veterinary Medicine (AREA)
  • Animal Behavior & Ethology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Physics & Mathematics (AREA)
  • Transplantation (AREA)
  • Microbiology (AREA)
  • Plant Pathology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Micro-Organisms Or Cultivation Processes Thereof (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
AU2021236669A 2020-03-18 2021-03-18 Anti-ceramide antibodies Pending AU2021236669A1 (en)

Applications Claiming Priority (3)

Application Number Priority Date Filing Date Title
US202062991232P 2020-03-18 2020-03-18
US62/991,232 2020-03-18
PCT/US2021/022914 WO2021188770A1 (en) 2020-03-18 2021-03-18 Anti-ceramide antibodies

Publications (1)

Publication Number Publication Date
AU2021236669A1 true AU2021236669A1 (en) 2022-11-10

Family

ID=77771401

Family Applications (1)

Application Number Title Priority Date Filing Date
AU2021236669A Pending AU2021236669A1 (en) 2020-03-18 2021-03-18 Anti-ceramide antibodies

Country Status (11)

Country Link
US (1) US20230167197A1 (https=)
EP (1) EP4121110A4 (https=)
JP (1) JP7809067B2 (https=)
KR (1) KR20230031814A (https=)
CN (1) CN115811987A (https=)
AU (1) AU2021236669A1 (https=)
BR (1) BR112022018682A2 (https=)
CA (1) CA3172201A1 (https=)
IL (1) IL296550A (https=)
MX (1) MX2022011591A (https=)
WO (1) WO2021188770A1 (https=)

Families Citing this family (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO2016022883A1 (en) 2014-08-07 2016-02-11 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies
EP4308231A4 (en) * 2021-03-16 2025-01-29 Memorial Sloan Kettering Cancer Center IMPROVING WOUND HEALING WITH ANTI-CERAMIDE ANTIBODIES

Family Cites Families (34)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US4579821A (en) 1981-11-23 1986-04-01 University Patents, Inc. Control of DNA sequence transcription
US4656134A (en) 1982-01-11 1987-04-07 Board Of Trustees Of Leland Stanford Jr. University Gene amplification in eukaryotic cells
US4713339A (en) 1983-01-19 1987-12-15 Genentech, Inc. Polycistronic expression vector construction
GR860984B (en) 1985-04-17 1986-08-18 Zymogenetics Inc Expression of factor vii and ix activities in mammalian cells
GB8611832D0 (en) 1986-05-15 1986-06-25 Holland I B Polypeptide
US4946778A (en) 1987-09-21 1990-08-07 Genex Corporation Single polypeptide chain binding molecules
US5132405A (en) 1987-05-21 1992-07-21 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5091513A (en) 1987-05-21 1992-02-25 Creative Biomolecules, Inc. Biosynthetic antibody binding sites
US5037743A (en) 1988-08-05 1991-08-06 Zymogenetics, Inc. BAR1 secretion signal
US5585362A (en) 1989-08-22 1996-12-17 The Regents Of The University Of Michigan Adenovirus vectors for gene therapy
US5283173A (en) 1990-01-24 1994-02-01 The Research Foundation Of State University Of New York System to detect protein-protein interactions
EP1400536A1 (en) 1991-06-14 2004-03-24 Genentech Inc. Method for making humanized antibodies
DE69233013T2 (de) 1991-08-20 2004-03-04 The Government Of The United States Of America As Represented By The Secretary Of National Institute Of Health, Office Of Technology Transfer Adenovirus vermittelter gentransfer in den gastrointestinaltrakt
US5252479A (en) 1991-11-08 1993-10-12 Research Corporation Technologies, Inc. Safe vector for gene therapy
FR2688514A1 (fr) 1992-03-16 1993-09-17 Centre Nat Rech Scient Adenovirus recombinants defectifs exprimant des cytokines et medicaments antitumoraux les contenant.
EP1024198A3 (en) 1992-12-03 2002-05-29 Genzyme Corporation Pseudo-adenoviral vectors for the gene therapy of haemophiliae
ES2156149T3 (es) 1992-12-04 2001-06-16 Medical Res Council Proteinas de union multivalente y multiespecificas, su fabricacion y su uso.
EP0705344B8 (en) 1993-06-24 2006-05-10 Advec Inc. Adenovirus vectors for gene therapy
AU687117B2 (en) 1993-10-25 1998-02-19 Canji, Inc. Recombinant adenoviral vector and methods of use
GB9518220D0 (en) 1995-09-06 1995-11-08 Medical Res Council Checkpoint gene
US7078387B1 (en) 1998-12-28 2006-07-18 Arch Development Corp. Efficient and stable in vivo gene transfer to cardiomyocytes using recombinant adeno-associated virus vectors
EP2289550A3 (en) 2000-01-27 2012-02-15 MedImmune, LLC Ultra high affinity neutralizing antibodies
MXPA05000511A (es) 2001-07-12 2005-09-30 Jefferson Foote Anticuepros super humanizados.
AU2005325801A1 (en) 2005-01-31 2006-08-03 Ablynx N.V. Method for generating variable domain sequences of heavy chain antibodies
EA201170357A1 (ru) * 2008-08-20 2012-05-30 Сентокор Орто Байотек Инк. Инженерные антитела к il-13: композиции, способы и применение
CA2785907A1 (en) 2009-12-29 2011-07-28 Emergent Product Development Seattle, Llc Ron binding constructs and methods of use thereof
US20130129723A1 (en) 2009-12-29 2013-05-23 Emergent Product Development Seattle, Llc Heterodimer Binding Proteins and Uses Thereof
US9833949B2 (en) 2011-08-29 2017-12-05 Impossible Objects, Inc. Apparatus for fabricating three-dimensional printed composites
US9209965B2 (en) 2014-01-14 2015-12-08 Microsemi Semiconductor Ulc Network interface with clock recovery module on line card
WO2016022883A1 (en) 2014-08-07 2016-02-11 Memorial Sloan-Kettering Cancer Center Anti-ceramide antibodies
TWI632160B (zh) * 2015-01-16 2018-08-11 中央研究院 具有標的部分及效應部分的分子構建體
CN118948892A (zh) * 2017-05-01 2024-11-15 朱诺治疗学股份有限公司 细胞疗法与免疫调节化合物的组合
WO2019237035A1 (en) * 2018-06-08 2019-12-12 Intellia Therapeutics, Inc. Compositions and methods for immunooncology
US10975169B1 (en) * 2019-09-27 2021-04-13 Memorial Sloan Kettering Cancer Center Methods for treating diabetic retinopathy using anti-ceramide monoclonal antibody 2A2

Also Published As

Publication number Publication date
CA3172201A1 (en) 2021-09-23
CN115811987A (zh) 2023-03-17
EP4121110A1 (en) 2023-01-25
KR20230031814A (ko) 2023-03-07
MX2022011591A (es) 2023-03-06
WO2021188770A1 (en) 2021-09-23
JP2023534779A (ja) 2023-08-14
IL296550A (en) 2022-11-01
JP7809067B2 (ja) 2026-01-30
EP4121110A4 (en) 2024-06-12
BR112022018682A2 (pt) 2023-02-14
US20230167197A1 (en) 2023-06-01

Similar Documents

Publication Publication Date Title
US20240174745A1 (en) Antibody Constructs for CLDN18.2 and CD3
US20240409655A1 (en) Anti-ox40 antibodies and methods of use
TWI774137B (zh) 針對cd3和bcma的抗體和自其製備的雙特異性結合蛋白
JP2018524997A (ja) Ｅｇｆｒｖｉｉｉ及びｃｄ３に結合する二重特異性抗体構築物
US20250122281A1 (en) Anti-human nr1 antibody derivative
JP7843824B2 (ja) 抗体および使用方法
JP2019514871A (ja) 骨髄性白血病の治療方法で使用するための、ｃｄ３３とｃｄ３に結合する二重特異性構築物の投与の方法
US12606619B2 (en) Human monoclonal antibodies against TIGIT for immune related diseases
JP7809067B2 (ja) 抗セラミド抗体
US20210395298A1 (en) Downstream processing of bispecific antibody constructs
WO2021097344A1 (en) Method for reduced aggregate formation in downstream processing of bispecific antigen-binding molecules
WO2021098748A1 (en) Methods of cancer treatment with anti-ox40 antibody in combination with chemotherapeutic agents
US20260083841A1 (en) Bispecific Molecule Stabilizing Composition
RU2852663C1 (ru) Антитела против cd3 и bcma и биспецифичные связывающие белки, полученные из них
HK40067877A (en) Antibodies to cd3 and bcma, and bispecific binding proteins made therefrom
EA051514B1 (ru) Полипептидные конструкции, селективно связывающиеся с cldn6 и cd3
EA048433B1 (ru) Конструкции на основе антител для связывания cldn18.2 и cd3

Legal Events

Date Code Title Description
HB Alteration of name in register

Owner name: CERAMEDIX HOLDING, LLC

Free format text: FORMER NAME(S): MEMORIAL SLOAN KETTERING CANCER CENTER; CERAMEDIX HOLDING, LLC; RICHARD KOLESNICK

Owner name: MEMORIAL SLOAN KETTERING CANCER CENTER

Free format text: FORMER NAME(S): MEMORIAL SLOAN KETTERING CANCER CENTER; CERAMEDIX HOLDING, LLC; RICHARD KOLESNICK